Vivent Health

Registered Principal Details

Business Or Interest:
HIV/AIDS prevention, care and treatment services; sexual health, including the screening, diagnosis and treatment of sexually transmitted infections; hepatitis C prevention, care and treatment services.

Lobbying Interests:
Areas related to HIV, AIDS, public health, public health funding, medical assistance/Medicaid reimbursement and eligibility, and sexual health, including sexually transmitted infections.

Contact
BK
Bill Keeton
820 N Plankinton Ave
Milwaukee, WI 53203
(414) 225-1572
bill.keeton@viventhealth.org
http://www.viventhealth.org

Authorized Lobbyists

Lobbyist Name Exclusive Duties Authorized On Withdrawn On
Bill Keeton Exclusive Duties No Authorized On 12/20/2022 Withdrawn On N/A
Daniel Romportl Exclusive Duties Yes Authorized On 1/24/2023 Withdrawn On N/A
Katie White Exclusive Duties Yes Authorized On 1/24/2023 Withdrawn On N/A
Ramie Zelenkova Exclusive Duties Yes Authorized On 1/24/2023 Withdrawn On N/A
Matthew Pagnotti Exclusive Duties No Authorized On 1/30/2023 Withdrawn On N/A

Lobbying Interests

Legislative Bills/Resolutions

Assembly Bill 465
Assembly Bill 465
Relating to: prohibiting gender transition medical intervention for individuals under 18 years of age.

Bill Text and History

Against
Notification Date
10/6/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Assembly Bill 634
Assembly Bill 634
Relating to: immunity for certain controlled substances offenses for aiders and aided persons.

Bill Text and History

For
Notification Date
11/29/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Assembly Bill 773
Assembly Bill 773
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)

Bill Text and History

For
Notification Date
12/13/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Assembly Bill 950
Assembly Bill 950
Relating to: excepting xylazine testing materials from the definition of drug paraphernalia and civil and criminal liability exemptions for distributing and administering xylazine testing products.

Bill Text and History

For
Notification Date
1/23/2024
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Senate Bill 595
Senate Bill 595
Relating to: immunity for certain controlled substances offenses for aiders and aided persons.

Bill Text and History

For
Notification Date
11/29/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Senate Bill 737
Senate Bill 737
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)

Bill Text and History

For
Notification Date
12/13/2023
First Communication Date
12/6/2023
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Senate Bill 875
Senate Bill 875
Relating to: excepting xylazine testing materials from the definition of drug paraphernalia and civil and criminal liability exemptions for distributing and administering xylazine testing products.

Bill Text and History

2023 Wisconsin Act 217

For
Notification Date
1/23/2024
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Budget Bill Subjects

Health Services: Departmentwide
Biennial budget bill treatment of matter relating to
Health Services: Departmentwide

Notification Date
7/31/2023
First Communication Date
1/5/2023
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.

Total Lobbying Effort

  2023
January - June
2023
July - December
2024
January - June
Total
Total Lobbying Expenditures 2023
January - June
$17,880.00
2023
July - December
$16,513.00
2024
January - June
$15,796.00
Total $50,189.00
Total Hours Communicating 2023
January - June
21.50
2023
July - December
10.25
2024
January - June
6.50
Total 38.25
Total Hours Other 2023
January - June
63.00
2023
July - December
42.50
2024
January - June
29.25
Total 134.75

Percent Allocation of Lobbying Effort

Legislative Bills/Resolutions

Relating to: immunity for certain controlled substances offenses for aiders and aided persons.
2023
January - June
2023
July - December
2024
January - June
2024
July - December
Total
2023
January - June
2023
July - December
5%
2024
January - June
20%
2024
July - December
Total 6%
Relating to: excepting xylazine testing materials from the definition of drug paraphernalia and civil and criminal liability exemptions for distributing and administering xylazine testing products.
2023
January - June
2023
July - December
2024
January - June
2024
July - December
Total
2023
January - June
2023
July - December
5%
2024
January - June
10%
2024
July - December
Total 4%
Relating to: immunity for certain controlled substances offenses for aiders and aided persons.
2023
January - June
2023
July - December
2024
January - June
2024
July - December
Total
2023
January - June
2023
July - December
5%
2024
January - June
20%
2024
July - December
Total 6%
Relating to: excepting xylazine testing materials from the definition of drug paraphernalia and civil and criminal liability exemptions for distributing and administering xylazine testing products.
2023
January - June
2023
July - December
2024
January - June
2024
July - December
Total
2023
January - June
2023
July - December
5%
2024
January - June
10%
2024
July - December
Total 4%
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
2023
January - June
2023
July - December
2024
January - June
2024
July - December
Total
2023
January - June
2023
July - December
40%
2024
January - June
20%
2024
July - December
Total 16%
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
2023
January - June
2023
July - December
2024
January - June
2024
July - December
Total
2023
January - June
2023
July - December
40%
2024
January - June
20%
2024
July - December
Total 16%

Budget Bill Subjects

2023
January - June
2023
July - December
2024
January - June
2024
July - December
Total
2023
January - June
100%
2023
July - December
2024
January - June
2024
July - December
Total 49%

Administrative Rulemaking Proceedings

No administrative rulemaking proceedings found.

Topics Not Yet Assigned A Bill Or Rule Number

No topics found.

Minor Efforts

No minor efforts found.

Other Matters

No other matters found.

Filed Statements of Lobbying Activity and Expenditures